Clinical trials: Vascular Malformations
Aortic Dissection, Thrombosis in Left Atrium and Right Axillary Artery
Multi-detector Computer Tomography Protocol Project: Chest Imaging Technique and Case Presentation
Multi-detector computer tomography protocol project: Chest imaging technique and case presentation.
- Conditions
- Aortic Dissection, Thrombosis in Left Atrium and Right Axillary Artery, Double IVC, May-Thurner Syndrome
- Trial name
- NCT01206751
- Testing
- Chest imaging technique and case presentation
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taipei Medical University WanFang Hospital
Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
The purpose of this study is to assess the effectiveness and safety of Trametinib (the "Study Drug") in patients with Ras/MAPK pathway driven vascular anomalies (VA). Trametinib has been approved by the U.S.
- Conditions
- Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies, Vascular Anomaly
- Trial name
- VATCH (NCT07549646)
- Testing
- Trametinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Children's Hospital of Philadelphia
Brain Injury, Central Nervous System Degenerative Disorder
Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS
This pilot clinical trial study will assess the inflammatory response of brain tumors or other central nervous system conditions in pediatric and adult patients using ferumoxytol-enhanced MRI.
- Conditions
- Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation
- Trial name
- NCT02452216
- Testing
- Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael Iv
Cerebral Palsy, Stroke
Feasibility of the Portable YouGrabber System
The aim of the study is to determine the feasibility of the portable version of the YouGrabber® system in children with central motor disorders.
- Conditions
- Cerebral Palsy, Stroke, Traumatic Brain Injury, Meningomyelocele
- Trial name
- YouGrabber (NCT02368223)
- Testing
- YouGrabber
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University Children's Hospital, Zurich
Cerebral Palsy, Stroke
Reliability of the Melbourne Assessment
The aim of the study is to investigate the reliability of the Melbourne Assessment.
- Conditions
- Cerebral Palsy, Stroke, Traumatic Brain Injury, Meningomyelocele
- Trial name
- NCT02595411
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Children's Hospital, Zurich
Congential Absence of Heart Structure, Congenital Malformation of Heart, Unspecified
Initiation of Resuscitation While Attached to the Cord With Congenital Heart Disease
Before birth, the placenta (a structure with many blood vessels attached to the inside of your womb) and the umbilical cord (the umbilical cord is attached to the placenta) are sending oxygen and nutrients from the mother's blood…
- Conditions
- Congential Absence of Heart Structure, Congenital Malformation of Heart, Unspecified, Hypoplastic Left Heart Syndrome, TGA - Transposition of Great Arteries
- Trial name
- INSPIRE-CHD (NCT03690245)
- Testing
- Initiation of Resuscitation While Attached to the Cord
- Where
- Canada
- Sponsor
- University of Alberta
Microcystic Lymphatic Malformation
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess…
- Trial name
- SELVA (NCT06239480)
- Testing
- QTORIN 3.9% Rapamycin Anhydrous Gel
- Where
- 15 sites in United States
- Volunteers
- 51 people
- Sponsor
- Palvella Therapeutics, Inc.
PIK3CA-related Overgrowth Spectrum, CLOVES Syndrome
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth.
- Conditions
- PIK3CA-related Overgrowth Spectrum, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly
- Trial name
- COSY (NCT05563831)
- Testing
- national registry
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hereditary Hemorrhagic Telangiectasia
Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients
OBJECTIVES: I. Collect data regarding the natural history of hereditary hemorrhagic telangiectasia (HHT). II. Establish genotype-phenotype correlations in HHT. III.
- Trial name
- NCT00004649
- Sponsor
- National Center for Research Resources (NCRR)
Hemorrhagic Stroke, Intracerebral, Cerebral Cavernous Malformation
CCM Blood Biomarker Validation Study
Cerebral cavernous malformations (CCMs), one of the most common microvascular malformations in the capillary beds of the brain, are susceptible to hemorrhagic stroke.
- Trial name
- NCT05148663
- Testing
- CCM Hemorrhagic Panel
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Ataxia Telangiectasia, ATM Gene Mutation
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia
This clinical trial investigates the effects of nicotinamide riboside (vitamin B3) on the disease course of patients with ataxia telangiectasia.
- Trial name
- NCT03962114
- Testing
- Vitamin B3
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Radboud University Medical Center
Port Wine Stain
The Role of Angiogenesis-related Pathways in the Development of Port Wine Stains
1. Port wine stain (PWS) is a congenital, progressive vascular malformation of human skin involving the superficial vascular plexus that occurs in estimated 3-5 children per 1,000 live births.
- Trial name
- NCT03948997
- Testing
- Pulsed dye laser (PDL)
- Volunteers
- 80 people
- Sponsor
- xjpfW
Cerebral Arteriovenous Malformation
Evaluation of Nidus Occlusion After Gamma Knife Radiosurgery of Cerebral Arteriovenous Malformations Using Magnetic Resonance Imaging
Cerebral arteriovenous malformations (AVMs) are abnormal vessels, connecting cerebral arteries and veins. They form a bundle which is called nidus.
- Trial name
- NCT03995823
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Lymphangiomatosis, Lymphedema
Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Background: Lymphatics are a type of vessel, similar to arteries and veins. Lymphatic disorders happen when these vessels don t work properly.
- Conditions
- Lymphangiomatosis, Lymphedema, Lymphangiectasia, Pulmonary Lymphangiectasia
- Trial name
- NCT02156115
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1)
Precision Medicine for Neurocutaneous Syndromes in Western China
The goal of this observational study (retrospective multicenter cohort study) is to learn if precision medicine approaches-including genetic testing, targeted drugs, and coordinated care from multiple specialists-can improve…
- Conditions
- Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1), Tuberous Sclerosis Complex (TSC), Sturge-Weber Syndrome (SWS)
- Trial name
- NCT07327164
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- West China Hospital
Intracranial Aneurysm, Brain Arterial Disease
Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform
BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices.
- Conditions
- Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases
- Trial name
- EVIDENCE (NCT04927156)
- Testing
- BALT medical devices
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 10,000 people
- Sponsor
- Balt Extrusion
Cutaneous Arteriovenous Malformations
Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations
Cutaneous Arteriovenous malformations (AVM's) rare congenital high-flow vascular malformations in which arteries and veins are directly connected through a complex web of abnormal arteries and veins instead of a normal capillary…
- Trial name
- NCT01774916
- Testing
- blood samples
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Telangiectasia, Hereditary Hemorrhagic
Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
We will address coagulation parameters in hereditary haemorrhagic telangiectasia (HHT) compared to controls.
- Trial name
- NCT00230659
- Testing
- Blood sample to be taken.
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Intracranial Aneurysm
Assessment of the Embolization of Neurovascular Lesions Using the Penumbra Smart Coil
The primary objective of this study is to gather post market data on the Penumbra SMART COIL® System (Smart System) in the treatment of intracranial aneurysms and other malformations.
- Trial name
- SMART (NCT02729740)
- Testing
- Penumbra Smart Coil, Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)
- Where
- 72 sites in United States, Canada
- Volunteers
- 995 people
- Sponsor
- Penumbra Inc.
Ovary Cancer
Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1
Tumours require a blood supply to provide them with oxygen and nutrients and to enable spread of cancer through blood vessels to other organs (metastasis).
- Trial name
- VALTIVE1 (NCT04523116)
- Where
- 4 sites in United Kingdom
- Volunteers
- 176 people
- Sponsor
- University of Manchester